BBA
KZR

Baker Bros. Advisors’s Kezar Life Sciences KZR Stock Holding History

Baker Bros. Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,195
Closed -$436K – 110
2022
Q4 		$436K Hold
6,195
– – ﹤0.01% 105
2022
Q3 		$533K Hold
6,195
– – ﹤0.01% 105
2022
Q2 		$512K Sell
6,195
-7,773
-56% -$686K ﹤0.01% 109
2022
Q1 		$2.32M Hold
13,968
– – 0.01% 99
2021
Q4 		$2.33M Hold
13,968
– – 0.01% 106
2021
Q3 		$1.21M Hold
13,968
– – 0.01% 116
2021
Q2 		$758K Hold
13,968
– – ﹤0.01% 118
2021
Q1 		$832K Hold
13,968
– – ﹤0.01% 121
2020
Q4 		$729K Sell
13,968
-43,528
-76% -$2.42M ﹤0.01% 121
2020
Q3 		$2.78M Sell
57,496
-2,504
-4% -$120K 0.01% 95
2020
Q2 		$3.11M Buy
+60,000
New +$3.03M 0.01% 86

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Baker Bros. Advisors's KZR Position: Q1 2023 in Review

Baker Bros. Advisors sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 6,195 shares — an estimated $436K sold.

Baker Bros. Advisors first reported a position in KZR in Q2 2020 and held it in 11 quarters. The position peaked at $3.11M in Q2 2020. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Baker Bros. Advisors reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 6,195 Kezar Life Sciences shares in Q1 2023, an estimated $436K.
  • Baker Bros. Advisors first reported a position in Kezar Life Sciences in Q2 2020 and held it in 11 quarters.
  • Baker Bros. Advisors's Kezar Life Sciences position peaked at $3.11M in Q2 2020.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.